Wave Life Sciences: setback for Huntington’s disease trials
30. March 2021. Yesterday, Wave Life Sciences gave an update on PRECISION-HD1 and PRECISION-HD2. Due to disappointing results, the biotechnology company has decided to stop the two Huntington’s disease trials. However, they will continue the development of a third drug candidate. The decision to stop the PRECISION-HD trials is not related to the stopped dosing of Tominersen…
Read more